Are you Looking for Help to Get Off Mirtazazepine or Help for Mirtazapine Withdrawal Symptoms? The Royal College of Psychiatrists have warned that coming off antidepressant can cause symptoms lasting for months and that doses should be gradually lowered over months. Our nonprofit has taken a holistic approach to Mirtazapine Withdrawal for 15 years, helping people in 78 countries. We know its hard to believe that anything natural can support Mirtazapine Withdrawals, but believe the thousands that have done our program. Tapering off Mirtazapine is critical to minimize the Mirtazapine Withdrawal Symptoms yet symptoms that include irritability, nausea, dizziness, nightmares, insomnia, brain zaps and headaches also can be lessened with specialized, natural nutraceuticals. Easing Mirtazapine Withdrawal Symptoms through a natural, comfortable approach is the most gentle way to Taper Off Mirtazapine. We are also drug/herb interaction experts to ensure you stay safe, and our mentoring is unmatched. If you need Help to Come Off Mirtazapines, please CONTACT Us Today.
SUCCESSFUL CHOICES YOU CAN MAKE RIGHT NOW
Our Mirtazapine weaning program is a slow taper that allows you to safely step down from Mirtazapine under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Mirtazapine until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Mirtazapine withdrawal and support well-being*
Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Mirtazapine Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Mirtazapine alone, work with our Prescription Drug Experts.
Imagine being Free of Mirtazapine Depedency
- Proven Program completed In-Home with Expert Guidance
- Slowly Wean Mirtazapine
- All-Natural Nutraceuticals to help Ease Mirtazapine Withdrawal
- Professional information on interactions
- Free Mentoring on our 24/7 private Discussion Board
- Free Assessment Upon Starting our Program (a $400 value)
Enter Discount Code ADFree for FREE Ground Shipping on your Withdrawal Program *USA & Canada Only
MIRTAZAPINE WITHDRAWAL SUCCESS STORIES
This experience has left me humbled and oh so grateful. Please let Point of Return work for you. They will provide the tools you need to succeed. More...
Vicky (Mirtazapine Withdrawal Success Story)
I owe it all to you, and everyone else at Point of Return. I am forever grateful, and I will never stop telling people about Point of Return. More...
Trudee (Mirtazapine Withdrawal Success Story)
I cannot say enough good things about the entire POR team. I will be forever grateful. Thank you from the bottom of my heart. More...
Mark (Mirtazapine Withdrawal Success Story)
EXPERIENCE and TEAMWORK
using a Natural Approach
Mirtazapine History and Information
A massive 2014 study of 22,610 people analyzed the affect on weight from the use of antidepressants. Mirtazapine (Remeron) was found to cause the greatest amount of weight gain, representing a 7% increase per year.There have been many reports of withdrawal symptoms upon the discontinuation of Mirtazapine or with a too rapid titration.
The FDA states, "Patients currently taking Mirtazapine (Remeron) should NOT discontinue treatment abruptly, due to risk of discontinuation symptoms. At the time that a medical decision is made to discontinue treatment with Remeron (Mirtazapine), a gradual reduction in the dose, rather than an abrupt cessation, is recommended."
Remeron (Mirtazapine) was introduced in the United States by the Dutch firm Organon International in 1996. Organon's first product was insulin in the 1920s and in the 30s they manufactured estrogens. Scherring-Plough Corporation acquired Organon in 2007, and in 2009 they was merged with Merck Pharmaceuticals. In October 2014 the U.S. government charged the manufacturer of Remeron with making improper financial incentives (kickbacks) to nursing homes to encourage the use of their drug. They were also charged with misrepresentation of drug prices and ordered to pay restitution for breaking the Federal Anti-Kickback Statute.
Mirtazapine is known as a Tetracyclic antidepressant and classified as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA), meaning Mirtazapine affects Norepinephrine and Serotonin.
Mirtazapine increases the release of both Serotonin and to a lesser degree Norepinephrine (Noradrenaline). Norepinephrine increases blood pressure, affects parts of the brain where attention and action is controlled. Along with Epinephrine, Norepinephrine creates the fight-or-flight response that increases heart rate and triggers the release of glucose while increasing blood flow to the skeletal muscle. Serotonin influences the cardiovascular, renal, immune and gastrointestinal systems, and is essential to regulate body temperature, heart rate, blood pressure and the sympathetic nervous system. Mirtazapine is also a potent antihistamine that contributes to its sedative qualities but is also known to cause weight gain and sugar cravings.
Mirtazapine Withdrawal Symptoms, Side Effects, Adverse Reactions
MIRTAZAPINE WITHDRAWAL SYMPTOMS MAY INCLUDE:
aggression, anxiety, balance issues , blurred vision, brain zaps, concentration impairment, constipation, crying spells, depersonalization, diarrhea, dizziness. electric shock sensations, fatigue, flatulence, flu-like symptoms, hallucinations, hostility, highly emotional, indigestion, irritability, impaired speech, insomnia, jumpy nerves, lack of coordination, lethargy, migraine headaches / increased headaches, nausea, nervousness, over-reacting to situations, paranoia, repetitive thoughts or songs, sensory & sleep disturbances, severe internal restlessness (akathisia), stomach cramps, tremors, tinnitus (ear ringing or buzzing), tingling sensations, troubling thoughts, visual hallucinations / illusions, vivid dreams, speech or visual changes, worsened depression
MIRTAZAPINE SIDE EFFECTS MAY INCLUDE:
Abdominal pain, Chills, Fever, Face Edema, Ulcer, Neck rigidity, Neck pain, Chest pain, Hypertension, Angina, Migraine, Goiter, Hypothyroidism, Thirst or dehydration, Weight loss, Abnormal healing, Diabetes, Arthritis or bursitis, Anxiety, Agitation, Twitching, Hostility, Reflexes increased, Convulsions, Sinusitis, Cough increased, Rash, Acne, Urinary retention
MIRTAZAPINE ADVERSE REACTIONS MAY INCLUDE: per PDR
Severe: cholecystitis, bronchospasm, bradycardia, myocardial infarction, exfoliative dermatitis, ocular hypertension, keratoconjunctivitis, hearing loss, muscle paralysis, seizures, GI obstruction, pancreatitis, cirrhosis, tendon rupture, bone fractures, asphyxia, pneumothorax, pulmonary embolism, heart failure, pancytopenia, serotonin syndrome, suicidal ideation, habdomyolysis, ventricular fibrillation, torsade de pointes, agranulocytosis, diabetic ketoacidosis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis
Moderate: hypercholesterolemia, constipation, hypertriglyceridemia, confusion, elevated hepatic enzymes, peripheral edema, hyperreflexia, delirium, dysarthria, ataxia, migraine, mania, hostility, hallucinations, depression, euphoria, dyskinesia, dystonic reaction, stomatitis, colitis, glossitis, dyspnea, angina, hypotension, dehydration, dysuria, hematuria, cystitis, urinary incontinence, impotence (erectile dysfunction), vaginitis, nephrolithiasis, urinary retention, hyperacusis, conjunctivitis, edema, aphasia, nystagmus, myoclonia, hypotonia, gastritis, oral ulceration, candidiasis, bone pain, phlebitis, lymphadenopathy, lymphocytosis, thrombocytopenia, leukopenia, anemia, gout, hyponatremia, diabetes mellitus, skin ulcer, ejaculation dysfunction, goiter, hypothyroidism, blepharitis, withdrawal, amnesia, myasthenia, peripheral vasodilation, hypertension, orthostatic hypotension, QT prolongation, neutropenia, hyperglycemia, bullous rash
Mild: drowsiness, weight gain, xerostomia, appetite stimulation, asthenia, dizziness, influenza, abnormal dreams, tremor, back pain, myalgia, increased urinary frequency, libido increase, emotional lability, paranoia, eructation, weight loss, nausea, epistaxis, syncope, fever, acne vulgaris, alopecia, xerosis, mastalgia, amenorrhea , dysmenorrhea, leukorrhea, otalgia, ocular pain, chills, headache, diplopia, tongue discoloration, hypersalivation, laryngitis, hiccups, petechiae, seborrhea, urticaria, polyuria, urinary urgency, breast enlargement, menorrhagia, parosmia, dysgeusia, paresthesias, hyperkinesis, hypoesthesia, vertigo, agitation, anxiety, abdominal pain, vomiting, anorexia, arthralgia, sinusitis, cough, polydipsia, rash, pruritus, photosensitivity, malaise, restlessness, infection
MIRTAZAPINE BOXED WARNINGS: per PDR:
Children, suicidal ideation
Mirtazapine is not FDA-approved for the treatment of depression in adolescents or children; safety and efficacy have not been established. Two manufacturer-sponsored, randomized, double-blind, placebo-controlled clinical trials in pediatric patients 7 to 18 years of age with major depressive disorder (n = 259) failed to demonstrate significant differences between mirtazapine and placebo with regard to the primary endpoint and all secondary endpoints. In October 2004, the FDA directed manufacturers of all antidepressants to add a boxed warning to their product labels detailing the risk of suicide in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4,400) lasting up to 16 weeks in pediatric patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants. The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment with antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in pediatrics or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or during dose changes. It is unknown if the suicidality risk in children or young adults extends to longer-term therapy. The possibility of a suicide attempt is inherent in patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder. All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment should be closely monitored during treatment with mirtazapine. In patients who exhibit worsening of depression or suicidality, a decision should be made to change or discontinue treatment. If discontinuing, the medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management to reduce the risk of overdose.
Mirtazapine References and Information
According to the FDA:
Nervous System: frequent: hypesthesia, apathy, depression, hypokinesia, vertigo, twitching, agitation, anxiety, amnesia, hyperkinesia, paresthesia; infrequent: ataxia, delirium, delusions, depersonalization, dyskinesia, extrapyramidal syndrome, libido increased, coordination abnormal, dysarthria, hallucinations, manic reaction, neurosis, dystonia, hostility, reflexes increased, emotional lability, euphoria, paranoid reaction; rare: aphasia, nystagmus, akathisia, stupor, dementia, diplopia, drug dependence, paralysis, grand mal convulsion, hypotonia, myoclonus, psychotic depression, withdrawal syndrome.
*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.
*The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.
* Testimonial results may vary person to person.
*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent and support throughout.
*This program is not meant to cure or prevent any disease or illness.
*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..